- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Ethics and Social Media-Where Do We Draw the Line?
A recent Facebook study has initiated a debate on privacy and ethicis concerns, with the Federal Trade Commission saying they'll soon be involved as well.
Scholars are exhilarated by the prospect of tapping into the vast troves of personal data collected by Facebook, Google, Amazon and a host of start-ups, which they say could transform social science research.
Once forced to conduct painstaking personal interviews with subjects, scientists can now sit at a screen and instantly play with the digital experiences of millions of Internet users. It’s the frontier of social science — experiments on people who may never even know they are subjects of study, let alone explicitly consent.
“This is a new era,” said Jeffrey T. Hancock, a Cornell University professor of communication and information science. “I liken it a little bit to when chemistry got the microscope.”
Read the article here: http://nyti.ms/1lU8Hoo
Source: The New York Times
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More
